Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Shirong Han"'
Autor:
Takayasu Kurata, Kazuhiko Nakagawa, Miyako Satouchi, Takashi Seto, Takeshi Sawada, Shirong Han, Masae Homma, Kazuo Noguchi, Naoyuki Nogami
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss , Pp 100458- (2021)
Introduction: Pembrolizumab plus chemotherapy significantly improved outcomes over chemotherapy alone as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) in phase 3 international trials. In the phase 1 KEYNOTE-011 s
Externí odkaz:
https://doaj.org/article/c84021ef7ede4bc6954aa6dc78bbbeae
Autor:
Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijima, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae-Weon Kim, Byoung-Gie Kim, Peng-Hui Wang, Ting-Chang Chang, Keiko Yamamoto, Shirong Han, McKenzie, Jodi, Orlowski, Robert J., Takuma Miura, Makker, Vicky, Yong Man Kim
Publikováno v:
Journal of Gynecologic Oncology; Mar2024, Vol. 35 Issue 2, p1-13, 13p
Autor:
Kan Yonemori, Mayu Yunokawa, Kimio Ushijima, Jun Sakata, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Takayuki Enomoto, Kazuhiro Takehara, Kosei Hasegawa, Wataru Yamagami, Keiko Yamamoto, Shirong Han, Lea Dutta, Robert Orlowski, Takuma Miura, Vicky Makker, Keiichi Fujiwara
Publikováno v:
Cancer Science. 113:3489-3497
Study 309/KEYNOTE-775 is a phase 3 open-label, randomized trial of lenvatinib plus pembrolizumab versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer with progression after platinum-based therapy. Primary endpoint
Autor:
Kei Muro, Kohei Shitara, Kensei Yamaguchi, Takaki Yoshikawa, Hironaga Satake, Hiroki Hara, Naotoshi Sugimoto, Nozomu Machida, Masahiro Goto, Hisato Kawakami, Kenji Amagai, Yasushi Omuro, Taito Esaki, Shuichi Hironaka, Tomohiro Nishina, Yoshito Komatsu, Hisahiro Matsubara, Shinichi Shiratori, Shirong Han, Taroh Satoh, Atsushi Ohtsu
Publikováno v:
Journal of Gastrointestinal Cancer.
Purpose Pembrolizumab demonstrated antitumor activity in programmed death ligand 1 positive (combined positive score (CPS) ≥ 1) gastric/gastroesophageal junction cancer in KEYNOTE-059 (third line or beyond), KEYNOTE-061 (second line), and KEYNOTE-0
Publikováno v:
2022 IEEE International Conference on Trust, Security and Privacy in Computing and Communications (TrustCom).
Autor:
Toshihiko Doi, Takashi Ogata, Shirong Han, Tomoko Takami, Toshikazu Moriwaki, Ken Kato, Fumio Nagashima, Naoyoshi Yatsuzuka, Ryu Ishihara, Pooja Bhagia, Kei Muro, Takashi Kojima, Keiichi Iwakami, Taroh Satoh, Hisato Kawakami
Publikováno v:
Esophagus
Background Safe and effective treatments for advanced esophageal cancer are an unmet need in Japan. We report results of a subgroup analysis of Japanese patients enrolled in KEYNOTE-181, a randomized, open-label, phase 3 study of pembrolizumab versus
Autor:
Kensei Yamaguchi, Keiko Minashi, Daisuke Sakai, Tomohiro Nishina, Yasushi Omuro, Masahiro Tsuda, Shiroh Iwagami, Hisato Kawakami, Taito Esaki, Naotoshi Sugimoto, Takashi Oshima, Ken Kato, Kenji Amagai, Hisashi Hosaka, Keigo Komine, Hisateru Yasui, Yuji Negoro, Kenji Ishido, Takahiro Tsushima, Shirong Han, Shinichi Shiratori, Tomoko Takami, Kohei Shitara
Publikováno v:
Cancer science. 113(8)
The KEYNOTE-659 study evaluated the efficacy and safety of first-line pembrolizumab plus S-1 and oxaliplatin (SOX) (cohort 1) or S-1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we upda
Autor:
Takashi Kojima, Hiroki Hara, Akihito Tsuji, Hisateru Yasui, Kei Muro, Taroh Satoh, Takashi Ogata, Ryu Ishihara, Masahiro Goto, Hideo Baba, Tomohiro Nishina, Shirong Han, Tomoko Sakata, Naoyoshi Yatsuzuka, Toshihiko Doi, Ken Kato
Publikováno v:
Esophagus : official journal of the Japan Esophageal Society. 19(4)
Background The phase 3 KEYNOTE-590 (NCT03189719) study showed first-line pembrolizumab plus chemotherapy significantly prolonged overall survival and progression-free survival versus placebo plus chemotherapy in patients with advanced unresectable or
Autor:
Kazuo Noguchi, Takayasu Kurata, Takeshi Sawada, Kazuhiko Nakagawa, Shirong Han, Masae Homma, Takashi Seto, Naoyuki Nogami, Miyako Satouchi
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss, Pp 100458-(2021)
Introduction Pembrolizumab plus chemotherapy significantly improved outcomes over chemotherapy alone as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) in phase 3 international trials. In the phase 1 KEYNOTE-011 st
Autor:
Shunji Takahashi, Nobumasa Mizuno, Kosei Hasegawa, Koji Matsumoto, Shirong Han, Tsutomu Takatsuki, Fan Jin, Kazuhiko Nakagawa
Publikováno v:
Annals of Oncology. 33:S480